LifeArc portfolio company RQ Bio’s antibody enters clinical trials
LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
2022, an excellent & productive year for @LifeArcVentures
👇Check out the team highlights below and be sure to sta… https://t.co/kJa4ZoMopA
2022 wrapped – our highlights from a pivotal year
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
MND Collaborative Partnership cautiously welcomes new Government funding
We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.
LifeArc announces £10m funding call for new chronic respiratory infection therapies
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge
£100m programme to transform care for people living with chronic lung conditions
More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.
LifeArc funds home monitoring trials for people with chronic respiratory conditions
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
AbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS